一线奥拉帕利维持治疗后复发的晚期卵巢癌患者后续治疗的疗效:PAOLA-1/ENGOT-ov25 试验结果
该事后分析评估 PAOLA-1/ENGOT-ov25 试验中接受一线奥拉帕利维持治疗的患者疾病进展后首次后续治疗(FST)的疗效,按进展发生在奥拉帕利维持治疗期间还是之后及 FST 类型分组,以 FST 至第二次后续治疗(SST)时间评价。806 例随机患者中 544 例(67.5%)进展并接受后续化疗。奥拉帕利联合贝伐珠单抗组中,维持治疗期间进展者 FST 至 SST 中位时间 6.1 个月,短于维持治疗之后进展者的 11.4 个月;多因素分析显示进展时机影响 FST 至 SST 时间(HR 0.65,95%CI 0.50-0.84;P=0.0011)。
要点
- 一线奥拉帕利维持治疗期间进展者 FST 至 SST 中位时间 6.1 个月,之后进展者为 11.4 个月。
- 多因素分析示维持治疗后进展(对比期间进展)影响 FST 至 SST 时间(HR 0.65,95%CI 0.50-0.84;P=0.0011)。
- 以含 PARP 抑制剂的铂类化疗为 FST 者,后续治疗疗效同样取决于进展发生在维持治疗期间还是之后。
核心结论
- 疾病进展相对于一线奥拉帕利维持治疗的时机可能影响后续铂类化疗的疗效。
- 作者指出结果应谨慎解读,但在所有亚组中,包括以铂类化疗联合 PARP 抑制剂再挑战为 FST 的患者,若进展发生在维持治疗之后而非期间,FST 至 SST 中位时间更长。
研究设计与样本
- PAOLA-1/ENGOT-ov25(NCT02477644)的事后分析,评估一线奥拉帕利维持治疗后疾病进展患者后续化疗的疗效。
- 通过 FST 至 SST 时间评价疗效,按进展发生在奥拉帕利维持治疗期间还是之后及 FST 类型分组。
- 在奥拉帕利联合贝伐珠单抗组采用多因素 Cox 模型识别影响后续化疗疗效的预后因素。
- 806 例随机患者中 544 例(67.5%)进展并接受后续化疗。
主要发现
- 奥拉帕利联合贝伐珠单抗组中,一线奥拉帕利维持治疗期间进展者 FST 至 SST 中位时间 6.1 个月,短于维持治疗之后进展者的 11.4 个月。
- 多因素分析表明,维持治疗之后进展(对比期间进展)独立于无铂间期或临床风险影响 FST 至 SST 时间(HR 0.65,95%CI 0.50-0.84;P=0.0011)。
- 在以铂类化疗联合 PARP 抑制剂为 FST 且进展并接受后续治疗的患者中,后续治疗疗效同样取决于进展发生在维持治疗期间还是之后。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression in the first-line setting is important to optimize postprogression treatments. We evaluated the efficacy of FST in patients from PAOLA-1/ENGOT-ov25 (NCT02477644) who received first-line olaparib maintenance. PATIENTS AND METHODS: This post hoc analysis evaluated the efficacy of subsequent chemotherapy following disease progression by assessing time from FST to second subsequent therapy (SST) according to whether progression occurred during versus after first-line olaparib maintenance and FST type. A multivariate Cox model was used in the olaparib plus bevacizumab arm to identify prognostic factors influencing the efficacy of subsequent chemotherapy. RESULTS: Of 806 randomized patients, 544 (67.5%) progressed and received subsequent chemotherapy. The median time from FST to SST was shorter in patients in the olaparib plus bevacizumab arm who progressed during first-line olaparib maintenance (6.1 months) than in those who progressed after first-line olaparib maintenance (11.4 months). Multivariate analysis indicated that progression after (versus during) first-line olaparib maintenance influenced time from FST to SST (hazard ratio 0.65, 95% confidence interval 0.50-0.84; P = 0.0011) independently of platinum-free interval or clinical risk. Among patients who progressed and received platinum-based chemotherapy with a PARP inhibitor as FST, the efficacy of subsequent therapies was also dependent on whether progression occurred during versus after first-line olaparib maintenance. CONCLUSIONS: These results suggest that the timing of disease progression relative to first-line olaparib maintenance may impact the efficacy of subsequent platinum-based chemotherapy. Although results should be interpreted with caution, across all subgroups, including patients who received platinum-based chemotherapy with PARP inhibitor rechallenge as FST, the median time from FST to SST was longer if progression occurred after versus during first-line olaparib maintenance.
引用
- Harter P, Marth C, Mouret-Reynier MA, et al. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2024. PMID: 39528049. doi:10.1016/j.annonc.2024.10.828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。